Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug resistance in cancer: mechanisms and tackling strategies
Tanweer Haider, Vikas Pandey, Nagma Banjare, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1125-1151
Closed Access | Times Cited: 216

Showing 26-50 of 216 citing articles:

Bacteria-Assisted Transport of Nanomaterials to Improve Drug Delivery in Cancer Therapy
Carla Jiménez‐Jiménez, Victor Moreno, Maria Vallet‐Regí
Nanomaterials (2022) Vol. 12, Iss. 2, pp. 288-288
Open Access | Times Cited: 34
CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics
Prashant Kumar Tiwari, Tin-Hsien Ko, Rajni Dubey, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 20
Overcoming biological barriers by virus-like drug particles for drug delivery
Yu‐Ling Chen, Chunjie Bao, Jia‐Lun Duan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 203, pp. 115134-115134
Closed Access | Times Cited: 20
Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways
Qiumei Fan, Xiaowei Liang, Zhipeng Xu, et al.
Phytomedicine (2023) Vol. 116, pp. 154884-154884
Open Access | Times Cited: 19
Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 8
Withanolides: Promising candidates for cancer therapy
Qiang Zhang, Yongkang Yuan, Shijie Cao, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 2, pp. 1104-1158
Closed Access | Times Cited: 7
Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines
Jaber Zafari, Nima Rastegar‐Pouyani, Fatemeh Javani Jouni, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Nano-flow cytometry unveils mitochondrial permeability transition process and multi-pathway cell death induction for cancer therapy
Liyun Su, Jingyi Xu, Cheng Lü, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer
Jagadeesh Rajaram, Lokesh Kumar Mende, Yaswanth Kuthati
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1120-1120
Open Access | Times Cited: 7
Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer
Wenli Liu, Yuqin Wang, Lijie Xia, et al.
Nutrients (2024) Vol. 16, Iss. 6, pp. 797-797
Open Access | Times Cited: 6
Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway
Rong Fu, Yujie You, Yuqing Wang, et al.
Biochemical Pharmacology (2024) Vol. 226, pp. 116345-116345
Closed Access | Times Cited: 6
lncRNAs: New players of cancer drug resistance via targeting ABC transporters
Mohammad Ebrahimnezhad, Sanaz Hassanzadeh Asl, Maede Rezaie, et al.
IUBMB Life (2024) Vol. 76, Iss. 11, pp. 883-921
Closed Access | Times Cited: 6
PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols
Natalya Maluchenko, Alexey V. Feofanov, Vasily M. Studitsky
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11441-11441
Open Access | Times Cited: 34
Hydrogels as promising therapeutic strategy for the treatment of skin cancer
Mahrokh Marzi, Mahsa Rostami Chijan, Elham Zarenezhad
Journal of Molecular Structure (2022) Vol. 1262, pp. 133014-133014
Closed Access | Times Cited: 27
Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy
Chang Liu, Cui Tang, Chunhua Yin
Carbohydrate Polymers (2022) Vol. 283, pp. 119097-119097
Closed Access | Times Cited: 26
A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer
Da‐Yong Hou, Man‐Di Wang, Ni-Yuan Zhang, et al.
Nano Letters (2022) Vol. 22, Iss. 10, pp. 3983-3992
Closed Access | Times Cited: 26
Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations
Chunyin Tang, Jieting Liu, Chunsong Yang, et al.
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1636-1636
Open Access | Times Cited: 26
Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment
Liyun Zhu, Danni Meng, Xu Wang, et al.
ACS Applied Bio Materials (2022) Vol. 5, Iss. 6, pp. 2481-2506
Closed Access | Times Cited: 23
Overexpression of YEATS2 Remodels the Extracellular Matrix to Promote Hepatocellular Carcinoma Progression via the PI3K/AKT Pathway
Xin Liu, Yi Hu, Cairong Li, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1850-1850
Open Access | Times Cited: 15
The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things
Yuan Fang, Xiaoli Zhang, Hanfei Huang, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia
Manuela Labbozzetta, Paola Poma, Monica Notarbartolo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4140-4140
Open Access | Times Cited: 14
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Shivam Singh, Heena Saini, Ashok Kumar Sharma, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
The evidence for repurposing anti-epileptic drugs to target cancer
Mir Aroosa, Jonaid Ahmad Malik, Sakeel Ahmed, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 9, pp. 7667-7680
Open Access | Times Cited: 13
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma
Patrick L. Sweeney, Yash Suri, Arnab Basu, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 4, pp. 858-73
Open Access | Times Cited: 13
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 5

Scroll to top